References
- BisgaardMLFengerKBulowSNiebuhrEMohrJFamilial adenomatous polyposis (FAP): frequency, penetrance, and mutation rateHum Mutat199431211258199592
- KennedyRDPotterDDMoirCREl-YoussefMThe natural history of familial adenomatous polyposis syndrome: a 24 year review of a single center experience in screening, diagnosis, and outcomesJ Pediatr Surg201449828624439586
- HalfEBercovichDRozenPFamilial adenomatous polyposisOrphanet J Rare Dis200942219822006
- LynchPMAyersGDHawkEThe safety and efficacy of celecoxib in children with familial adenomatous polyposisAm J Gastroenterol20101051437144320234350
- BulowCVasenHJarvinenHBjorkJBisgaardMLBulowSIleorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposisGastroenterology20001191454146011113066
- KirchhoffPClavienPAHahnloserDComplications in colorectal surgery: risk factors and preventive strategiesPatient Saf Surg20104520338045
- BooijKAMathus-VliegenEMTaminiauJAEvaluation of 28 years of surgical treatment of children and young adults with familial adenomatous polyposisJ Pediatr Surg20104552553220223315
- FriederichPde JongAEMathus-VliegenLMRisk of developing adenomas and carcinomas in the ileal pouch in patients with familial adenomatous polyposisClin Gastroenterol Hepatol200861237124218848811
- KimBGiardielloFMChemoprevention in familial adenomatous polyposisBest Pract Res Clin Gastroenterol20112560762222122775
- EberhartCECoffeyRJRadhikaAGiardielloFMFerrenbachSDuBoisRNUp-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomasGastroenterology1994107118311887926468
- SinicropeFALemoineMXiLReduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancersGastroenterology199911735035810419916
- TudykaVNClarkSKSurgical treatment in familial adenomatous polyposisAnn Gastroenterology201225201206
- VasenHFMosleinGAlonsoAGuidelines for the clinical management of familial adenomatous polyposis (FAP)Gut20085770471318194984
- National Comprehensive Cancer NetworkClinical practice guidelines in oncology. Genetic/familial high-risk assessment: colorectal version 22014 Available from: nccn.org/professionals/physician_gls/f_guidelines.aspAccessed July 25, 2014
- SteinbachGLynchPMPhillipsRKThe effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposisN Engl J Med20003421946195210874062
- RigauJPiqueJMRubioEPlanasRTarrechJMBordasJMEffects of long-term sulindac therapy on colonic polyposisAnn Intern Med19911159529541659272
- GiardielloFMHamiltonSRKrushAJTreatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposisN Engl J Med1993328131313168385741
- BertagnolliMMEagleCJZauberAGCelecoxib for the prevention of sporadic colorectal adenomasN Engl J Med200635587388416943400
- HuangKGutierrezLPBulowSClinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort studyFam Cancer20111030330821359561
- BhalaNEmbersonJMerhiAVascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsLancet201338276977923726390
- WangDDuBoisRNThe role of COX-2 in intestinal inflammation and colorectal cancerOncogene20102978178819946329
- BertagnolliMMEagleCJZauberAGFive-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib TrialCancer Prev Res (Phila)2009231032119336730